Evidence map›Paper›PMID 28259994›Full record

ArticleInternational journal of molecular medicine2017

Overexpression of wild-type p21Ras plays a prominent role in colorectal cancer.

Shuang Bai, Qiang Feng, Xin-Yan Pan, Hong Zou, Hao-Bin Chen, Peng Wang, Xin-Liang Zhou, Yan-Ling Hong, Shu-Ling Song, Ju-Lun Yang

Open access · hybridAbstract read
In one paragraph

Article in International journal of molecular medicine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
0.7field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 20 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Cancer diagnosis & prognosis
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Shuang BaiFaculty of Medicine, Kunming University of Science and Technology, Kunming, Yunnan 650500, P.R. China.
Qiang FengDepartment of Pathology, Kunming General Hospital, Kunming, Yunnan 650032, P.R. China.
Xin-Yan PanDepartment of Pathology, Kunming General Hospital, Kunming, Yunnan 650032, P.R. China.
Hong ZouDepartment of Pathology, Kunming General Hospital, Kunming, Yunnan 650032, P.R. China.
Hao-Bin ChenDepartment of Pathology, Kunming General Hospital, Kunming, Yunnan 650032, P.R. China.
Peng WangFaculty of Medicine, Kunming University of Science and Technology, Kunming, Yunnan 650500, P.R. China.
Xin-Liang ZhouFaculty of Medicine, Kunming University of Science and Technology, Kunming, Yunnan 650500, P.R. China.
Yan-Ling HongDepartment of Pathology, Kunming Medical University, Kunming, Yunnan 650031, P.R. China.
Shu-Ling SongDepartment of Pathology, Kunming General Hospital, Kunming, Yunnan 650032, P.R. China.
Ju-Lun YangFaculty of Medicine, Kunming University of Science and Technology, Kunming, Yunnan 650500, P.R. China.
Kunming General Hospital of Chengdu Military Command · CNKunming University of Science and Technology · CNKunming Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Colorectal cancer (CRC) is the most common gastrointestinal type of cancer. The overexpression of Ras proteins, particularly p21Ras, are involved in the development of CRC. However, the subtypes of the p21Ras proteins that are overexpressed and the mutation status remain unknown restricting the development of therapeutic antibodies targeting p21Ras proteins. The present study aimed to investigate the mutation status of ras genes associated with Ras proteins that are overexpressed in CRC and explore whether or not wild-type p21Ras could be a target for CRC therapy. p21Ras expression was examined immunohistochemically in normal colorectal epithelium, benign lesions and malignant colorectal tumor tissues by monoclonal antibody (Mab) KGH-R1 which is able to react with three types of p21Ras proteins: H-p21Ras, N-p21Ras and K-p21Ras. Then, the expression levels of p21Ras subtypes were determined in CRC by a specific Mab for each p21Ras subtype. Mutation status of ras genes in p21Ras-overexpressing CRC was detected by DNA sequencing. There was rare p21Ras expression in normal colorectal epithelium but a high level of p21Ras expression in CRC, with a significant increase from normal colorectal epithelium to inflammatory polyps, low-grade intraepithelial neoplasia, high-grade intraepithelial neoplasia and invasive colorectal adenocarcinoma, respectively. Overexpression of K-p21Ras was found in all CRC tissues tested, overexpression of N-p21Ras was found in 85.7% of the CRC tissues, while H-p21Ras expression was not found in any CRC tissue. DNA sequencing showed that there were no K-ras mutations in 60% of the K-p21Ras-overexpressing CRC, while 40% of the CRC tissues harbored K-ras mutations. N-ras mutations were not found in any N-p21Ras-overexpressing CRC. Our findings indicate that overexpression of wild-type p21Ras may play a prominent role in the development of CRC in addition to ras mutations and could be a promising target for CRC therapy.

Indexed as

Gene Expression Regulation, EnzymologicGene Expression Regulation, NeoplasticMutationAdultAgedAged, 80 and overColorectal NeoplasmsFemaleHumansIntestinal MucosaMaleMiddle AgedProto-Oncogene Proteins p21(ras)HRAS protein, humanProto-Oncogene Proteins p21(ras)

Identifiers

PMID28259994
PMCPMC5360420
OpenAlexW2590800000

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.